biostudies-literatureUnknown9Rocco PRMConselho Nacional de Desenvolvimento Científico e TecnológicoFinanciadora de Estudos e Projetos<h4>Background</h4>Nitazoxanide exerts antiviral activity <i>in vitro</i> and <i>in vivo</i> and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain.<h4>Methods</h4>A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinicalFrontiers in medicine844728https://www.ebi.ac.uk/biostudies/studies/S-EPMC9043450biostudies-literatureNitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.PMC9043450da Silva JDGBarbosa LCVFernandes APSMCaldeira DAFHaag FFonseca FGLuiz RRCabral ACNogueira CMBBuchele KSPelosi PRocco PRMMorais SAraujo-Filho JAde Oliveira MCTierno PFGMMSverdloff CMoura ASReis JSJunqueira AAFRabello ESilva RGFCruz FFMamede MMSMartins CMda Costa LATJLapa-E-Silva JRCarajeleascow RJunior JCSoares CRPAlvarenga PPMCamargos VNFelix NSFranchini KGMattos-Silva PSilva PLde Avila REfalseNitazoxanide in Patients Hospitalized With COVID-19 Pneumonia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.<h4>Background</h4>Nitazoxanide exerts antiviral activity <i>in vitro</i> and <i>in vivo</i> and anti-inflammatory effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain.<h4>Methods</h4>A multicentre, randomized, double-blind, placebo-controlled trial was conducted in 19 hospitals in Brazil. Hospitalized adult patients requiring supplemental oxygen, with COVID-19 symptoms and a chest computed tomography scan suggestive of viral pneumonia or positive RT-PCR test for COVID-19 were enrolled. Patients were randomized 1:1 to receive nitazoxanide (500 mg) or placebo, 3 times daily, for 5 days, and were followed for 14 days. The primary outcome was intensive care unit admission due to the need for invasive mechanical ventilation. Secondary outcomes included clinical2022-01-01T00:00:00Z20222026-04-08T13:21:06.895Z2025-04-20T03:09:02.123ZS-EPMC90434503549233510.3389/fmed.2022.844728